Biohit Oyj acquires the rights to the UFT300 test, which is a rapid test for the diagnosis of Helicobacter pylori infection. Along with the agreement, the Italian developer, Advanced Biomedical Systems s.r.l. (ABS) gives Biohit the patent and distribution rights for the test. The purchase price is EUR 350,000 and the new H. pylori quick test will be incorporated into Biohit’s product range during the fourth quarter, 2013.
UFT300 is the only test available on the market which permits the reading of the result as well as confirmation within 5 minutes from the sample insertion; UFT300 combines the superior performance characteristics (sensitivity 94,5%, specificity 100%, accuracy 97,5%) with the maximum speed if compared with all the competitors' tests commercially available worldwide (1). After a transition period, the rights to the earlier version of the test (UFT200) will also be transferred to Biohit.
CEO Semi Korpela, Biohit Oyj: "This is bad news for helicobacter. Our test is superior.”
Source (1): Vaira D et al 2010 Accuracy of a new ultrafast rapid urease test to diagnose Helicobacter pylori infection in 1000 consecutive dyspeptic patients
CEO Semi Korpela, Biohit Oyj Tel. +358 9 773 861 firstname.lastname@example.org www.biohithealthcare.com
This news release was distributed by GlobeNewswire, www.globenewswire.com – a NASDAQ OMX company